CareDx
CDNACareDx is a precision medicine company specializing in genomics-based information and non-invasive molecular testing for transplant patients.
Earnings
Next report
Date not yet announcedValuation & ratios
Segments
Competitors
By market cap
By revenue growth
Profile
CareDx is a precision medicine company specializing in genomics-based information and non-invasive molecular testing for transplant patients. The company provides an integrated suite of solutions including laboratory-developed tests, digital health technologies, and patient management tools designed to improve outcomes across the organ transplant lifecycle. Their core value proposition centers on a concentrated go-to-market model that serves transplant centers with a comprehensive portfolio to drive clinical adherence and operational efficiency.
CareDx is the leading provider of genomics-based information for transplant patients, utilizing a differentiated high-touch service model within a concentrated market of transplant centers.
FAQ
- What is CareDx's market cap?
- CareDx (CDNA) has a market capitalization of $3.7B and trades on NASDAQ.
- What is CareDx's revenue and profitability?
- CareDx generated $497.4M in trailing twelve-month revenue with net income of $128.6M, representing a net margin of 25.9%. Gross margin stands at 65.5%. The latest reported period is Q3 2026.
- Who are CareDx's competitors?
- CareDx's key competitors include Natera, Insight Molecular Diagnostics Inc. Common Stock, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
- What subsidiaries does CareDx have?
- CareDx's subsidiaries include Ottr, TransplantHero.
- Where is CareDx headquartered?
- CareDx is headquartered in United States of America and employs approximately 643 people. It has been publicly traded since 2014.
